Abstract:Prostate cancer (PCa) is a complex disease driven by genomic alterations, and understanding the immune response to these alterations can provide valuable insights into the pathogenesis. This study aimed to explore the immunogenicity of proteins encoded by PCa driver genes and to further identify corresponding autoantibodies as potential biomarkers. Through a comprehensive screening process involving bioinformatics analysis based on published studies, a set of PCa driver genes was identified for further investigation. Three strategies were employed to identify candidate driver genes: (1) utilizing the IntOGen database (Martínez-Jiménez et.al, Nature Reviews Cancer 2020), nine cohorts comprising 1503 primary PCa patient samples were analyzed, resulting in the identification of 63 PCa driver genes, with the top 20 genes exhibiting high mutation rates and frequencies in these cohorts; (2) employing the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, 16 driver genes that were enriched in prostate cancer pathways were identified from the initial 63 genes; (3) referring to a published article (Dietlein et.al, Nature Genetics 2020), the top 17 driver genes specific to prostate cancer across 28 tumor types were selected. A final set of 15 PCa driver genes, which appeared in at least two of the screening strategies, were included in subsequent analyses. To assess the presence of autoantibodies targeting proteins encoded by these 15 PCa driver genes, an enzyme-linked immunosorbent assay (ELISA) was performed. Autoantibodies to proteins encoded by the selected PCa driver genes were evaluated using serum samples from PCa patients and normal controls. The results revealed that seven out of the 15 autoantibodies showed significantly elevated levels in the sera of PCa patients compared to normal controls. Notably, the autoantibody targeting SPOP (speckle-type POZ protein) exhibited the highest frequency of 42.4%, followed by the autoantibody to PTEN (phosphatase and tensin homolog) at 37.4% in the PCa group. These findings suggest that proteins encoded by PCa driver genes may possess immunogenic properties, leading to the production of corresponding autoantibodies. The identification of specific autoantibodies associated with PCa driver genes could offer novel opportunities for the discovery of autoantibody-based biomarkers in prostate cancer. Further validation and characterization of these autoantibodies are warranted to evaluate their diagnostic or prognostic potential and elucidate their functional roles in PCa pathogenesis. Citation Format: Jian-Ying Zhang, Cuipeng Qiu, Xiao Wang, Bofei Wang. Exploring autoantibody response to proteins encoded by prostate cancer driver genes [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr A027.

Identification and preliminary study of immunogens involved in autoimmune prostatitis in human males.

Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis

Characterization of Circulating CD4+CD25High Regulatory T Cells in Men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Crucial role of interferon-gamma in experimental autoimmune prostatitis

Multi-Factors Including Inflammatory/Immune, Hormones, Tumor-Related Proteins And Nutrition Associated With Chronic Prostatitis Nih Iiia Plus B And Iv Based On Famhes Project

Multi-factors including Inflammatory/Immune, Hormones, Tumor-related Proteins and Nutrition associated with Chronic Prostatitis NIH IIIa+b and IV based on FAMHES project

Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease

Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray.

Association between autoimmunity-related disorders and prostate cancer: A Mendelian randomization study

The causative effect of CXCR7 on experimental autoimmune prostatitis injury and fibrosis

Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse

Gut Microflora Modulates Th17/Treg Cell Differentiation in Experimental Autoimmune Prostatitis via the Short-Chain Fatty Acid Propionate

Seminal plasma cytokine levels in the diagnosis of chronic pelvic pain syndrome

Assessing the causal relationship between immune cells and prostatitis: evidence from bidirectional mendelian randomization analysis

Comparison of cytokine levels in prostatic secretion between the IIIa and IIIb subtypes of prostatitis

Genetic Polymorphisms of IFNG, IFNGR1, and Androgen Receptor and Chronic Prostatitis/Chronic Pelvic Pain Syndrome in a Chinese Han Population

4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy for chronic prostatitis

NLRP3-mediated IL-1β in regulating the imbalance between Th17 and Treg in experimental autoimmune prostatitis

Unraveling CCL20's role by regulating Th17 cell chemotaxis in experimental autoimmune prostatitis

Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines

Abstract A027: Exploring autoantibody response to proteins encoded by prostate cancer driver genes